Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18752369 | 0.81 | POLB (0.47) | SLC6A2SLC6A4SLC6A3POLBGAA | |
| SCHEMBL21725470 | 0.77 | UHRF1 (0.43) | SLC6A2SLC6A4SLC6A3CRHR1 | |
| SCHEMBL23667315 | 0.76 | MAP4K1 (0.37) | CRHR1 | |
| SCHEMBL20676684 | 0.76 | KDM4E (0.46) | SLC6A2SLC6A4SLC6A3GAAP2RX3 | |
| SCHEMBL19121635 | 0.74 | GAA (0.44) | POLBGAAGFERP2RX3P2RX2 | |
| SCHEMBL22448807 | 0.74 | P2RX3 (0.40) | POLBGAAGFERP2RX3P2RX2 | |
| SCHEMBL19308587 | 0.73 | GAA (0.47) | POLBGAAGFERP2RX3P2RX2 | |
| SCHEMBL2632721 | 0.73 | ACHE (0.50) | POLBCYP3A4LPAR1KDM4ETDP1 | |
| SCHEMBL18929225 | 0.73 | NOS3 (0.39) | SLC6A2SLC6A4SLC6A3CRHR1 | |
| SCHEMBL1054720 | 0.72 | ALDH1A1 (0.46) | SLC6A2SLC6A4SLC6A3CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SLC6A2 3423/4885SLC6A4 3073/4885SLC6A3 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.